

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change – May 10, 2007

NOTICE OF STATUS CHANGE

This study is temporarily closed to patient accrual effective Thursday, May 10, 2007. Accrual to dose level 0 has been met.

Please retain this notice with the protocol.